Exploration of biomarkers of the efficacy of trabectedin in soft tissue sarcoma
| Project/Area Number |
18K15303
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 悪性軟部腫瘍 / バイオマーカー / 骨軟部腫瘍 |
|---|
| Outline of Final Research Achievements |
There are several chemotherapy regimen to treat soft tissue sarcoma. Trabectedin is one of the drugs for advanced soft tissue sarcoma. It is important to reveal the biomarker to predict the efficacy of trabectedin. The purpose of this research was to elucidate the biomarker of trabectedin to predict the efficacy through genomic analysis of tumor specimens and mechanism of resistance to trabectedin. We identified several possible genomic biomarker, and will perform more analysis in the future.
|
| Academic Significance and Societal Importance of the Research Achievements |
悪性軟部腫瘍に対する化学療法薬の複数選択肢がある中で、そのバイオマーカーを同定することが求められている。本研究は進行例悪性軟部腫瘍に対して保険適応となっているトラベクテジンの奏効性を予測する指標を腫瘍の遺伝子解析を行うことで、同定することを目的とした。本研究の結果、効果予測の候補となる遺伝子が挙げられたためさらなる解析を行う予定である。
|
Report
(3 results)
Research Products
(8 results)
